Collins Joseph F, Donta Sam T, Engel Charles C, Baseman Joel B, Dever Lisa L, Taylor Thomas, Boardman Kathy D, Martin Suzanne E, Wiseman Annette L, Feussner John R
Cooperative Studies Program Coordinating Center, VA Medical Center, Perry Point, MD 21902, USA.
Control Clin Trials. 2002 Jun;23(3):333-53. doi: 10.1016/s0197-2456(02)00192-7.
Many veterans who were deployed to the Persian Gulf during the 1990-1991 Gulf War developed multiple unexplained symptoms such as pain, fatigue, and neurocognitive problems. This constellation of symptoms has been termed Gulf War Veterans' Illnesses (GWVI). Although there is no proven explanation for the cause of GWVI, one fairly widespread explanation is systemic Mycoplasma fermentans infection. The Antibiotic Treatment Trial of GWVI is a randomized placebo-controlled trial to determine whether a 1-year course of doxycycline treatment in deployed Gulf War veterans with GWVI and testing as Mycoplasma species positive will improve their overall functional status as measured by the Physical Component Summary of the SF-36V questionnaire. The study of a multisymptom illness such as GWVI is complicated by the nonspecific nature of the illness, the unknown etiology, and the lack of a widely accepted outcome measure. The presumption of mycoplasma infection raises concerns regarding the methodology for determination of mycoplasma infection, the choice of treatment, and the duration of treatment. However, such a presumption allows the formulation of a clear testable hypothesis that can be tested with treatments with known rates of adverse events and known activity against Mycoplasma species. This paper describes the major issues faced by the investigators during planning, the study design, the patient screening results, and the baseline characteristics of the study patients. There were 2712 patients screened for study entry at 26 Department of Veterans Affairs and two Department of Defense medical centers. Of these, 491 met all study entry criteria and were randomized to either 1 year of doxycycline (200 mg/day) or 1 year of placebo. All patients were seen monthly during treatment and at 6 months after the end of treatment. Study patients had a mean age of 41 years and were mostly male (86%), white (64%), married (68%), and employed full-time (71%).
许多在1990 - 1991年海湾战争期间被部署到波斯湾的退伍军人出现了多种不明原因的症状,如疼痛、疲劳和神经认知问题。这一系列症状被称为海湾战争退伍军人病(GWVI)。尽管GWVI的病因尚无经证实的解释,但一种相当普遍的解释是全身性发酵支原体感染。GWVI抗生素治疗试验是一项随机安慰剂对照试验,旨在确定在被部署的患有GWVI且检测为支原体阳性的海湾战争退伍军人中,为期1年的强力霉素治疗是否会改善他们的整体功能状态,这一状态通过SF - 36V问卷的身体成分总结来衡量。对GWVI这样一种多症状疾病的研究因该疾病的非特异性、病因不明以及缺乏广泛接受的结局指标而变得复杂。支原体感染的推测引发了对支原体感染测定方法、治疗选择和治疗持续时间的担忧。然而,这种推测使得能够形成一个清晰的可检验假设,该假设可以通过已知不良事件发生率和已知抗支原体活性的治疗来进行检验。本文描述了研究人员在规划、研究设计、患者筛查结果以及研究患者基线特征方面面临的主要问题。在26个退伍军人事务部和2个国防部医疗中心对2712名患者进行了研究入组筛查。其中,491名患者符合所有研究入组标准,并被随机分为接受为期1年的强力霉素(200毫克/天)治疗或为期1年的安慰剂治疗。所有患者在治疗期间每月接受检查,并在治疗结束后6个月接受检查。研究患者的平均年龄为41岁,大多数为男性(86%)、白人(64%)、已婚(68%)且全职工作(71%)。